Jan 21, 2014, 09.12 AM IST
Aurobindo Pharma held a conference call post markets yesterday clarifying on all the details on the Actavis acquisition – What were the details and who were the investors on the call? Ekta Batra of CNBC-TV18 has the details.
Tags Aurobindo Pharma, conference call, markets, Actavis, acquisition, investors, Ekta Batra
Like this story, share it with millions of investors on M3
Aurobindo's Actavis acquisition: The fine print
Aurobindo Pharma held a conference call post markets yesterday clarifying on all the details on the Actavis acquisition – What were the details and who were the investors on the call? Ekta Batra of CNBC-TV18 has the details.
Like this story, share it with millions of investors on M3
Aurobindo's Actavis acquisition: The fine print
Aurobindo Pharma held a conference call post markets yesterday clarifying on all the details on the Actavis acquisition – What were the details and who were the investors on the call? Ekta Batra of CNBC-TV18 has the details.
Aurobindo Pharm stock price
On January 21, 2014, at 09:25 hrs Aurobindo Pharma was quoting at Rs 418.50, up Rs 9.25, or 2.26 percent. The 52-week high of the share was Rs 422.05 and the 52-week low was Rs 127.15.
The company's trailing 12-month (TTM) EPS was at Rs 21.66 per share as per the quarter ended September 2013. The stock's price-to-earnings (P/E) ratio was 19.32. The latest book value of the company is Rs 100.88 per share. At current value, the price-to-book value of the company is 4.15.
Action in Aurobindo Pharma
Anda sedang membaca artikel tentang
Aurobindo's Actavis acquisition: The fine print
Dengan url
http://sehatkafein.blogspot.com/2014/01/aurobindos-actavis-acquisition-fine.html?m=0
Anda boleh menyebar luaskannya atau mengcopy paste-nya
Aurobindo's Actavis acquisition: The fine print
namun jangan lupa untuk meletakkan link
Aurobindo's Actavis acquisition: The fine print
sebagai sumbernya
0 komentar:
Posting Komentar